AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Fundamental Analysis

NASDAQ:AMPH • US03209R1032

27.51 USD
-1.08 (-3.78%)
Last: Feb 12, 2026, 02:47 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to AMPH. AMPH was compared to 191 industry peers in the Pharmaceuticals industry. While AMPH belongs to the best of the industry regarding profitability, there are some minor concerns on its financial health. AMPH scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, AMPH could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

9

1. Profitability

1.1 Basic Checks

  • AMPH had positive earnings in the past year.
  • In the past year AMPH had a positive cash flow from operations.
  • AMPH had positive earnings in each of the past 5 years.
  • Each year in the past 5 years AMPH had a positive operating cash flow.
AMPH Yearly Net Income VS EBIT VS OCF VS FCFAMPH Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M 100M 150M 200M

1.2 Ratios

  • Looking at the Return On Assets, with a value of 6.70%, AMPH belongs to the top of the industry, outperforming 87.96% of the companies in the same industry.
  • AMPH's Return On Equity of 14.37% is amongst the best of the industry. AMPH outperforms 87.96% of its industry peers.
  • With an excellent Return On Invested Capital value of 8.51%, AMPH belongs to the best of the industry, outperforming 86.91% of the companies in the same industry.
  • Measured over the past 3 years, the Average Return On Invested Capital for AMPH is in line with the industry average of 12.66%.
  • The last Return On Invested Capital (8.51%) for AMPH is well below the 3 year average (12.92%), which needs to be investigated, but indicates that AMPH had better years and this may not be a problem.
Industry RankSector Rank
ROA 6.7%
ROE 14.37%
ROIC 8.51%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
AMPH Yearly ROA, ROE, ROICAMPH Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 10 15 20

1.3 Margins

  • The Profit Margin of AMPH (15.43%) is better than 87.43% of its industry peers.
  • AMPH's Profit Margin has improved in the last couple of years.
  • AMPH's Operating Margin of 20.73% is amongst the best of the industry. AMPH outperforms 88.48% of its industry peers.
  • AMPH's Operating Margin has improved in the last couple of years.
  • AMPH has a Gross Margin of 49.36%. This is in the better half of the industry: AMPH outperforms 64.40% of its industry peers.
  • AMPH's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 20.73%
PM (TTM) 15.43%
GM 49.36%
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
AMPH Yearly Profit, Operating, Gross MarginsAMPH Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30 40 50

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. Health

2.1 Basic Checks

  • AMPH has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, AMPH has less shares outstanding
  • AMPH has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for AMPH has been reduced compared to a year ago.
AMPH Yearly Shares OutstandingAMPH Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
AMPH Yearly Total Debt VS Total AssetsAMPH Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • An Altman-Z score of 2.47 indicates that AMPH is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a decent Altman-Z score value of 2.47, AMPH is doing good in the industry, outperforming 64.40% of the companies in the same industry.
  • The Debt to FCF ratio of AMPH is 5.49, which is a neutral value as it means it would take AMPH, 5.49 years of fcf income to pay off all of its debts.
  • AMPH's Debt to FCF ratio of 5.49 is amongst the best of the industry. AMPH outperforms 83.25% of its industry peers.
  • A Debt/Equity ratio of 0.78 indicates that AMPH is somewhat dependend on debt financing.
  • The Debt to Equity ratio of AMPH (0.78) is worse than 70.16% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 5.49
Altman-Z 2.47
ROIC/WACC0.95
WACC8.99%
AMPH Yearly LT Debt VS Equity VS FCFAMPH Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M 400M 600M

2.3 Liquidity

  • AMPH has a Current Ratio of 3.12. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
  • AMPH has a Current ratio (3.12) which is in line with its industry peers.
  • AMPH has a Quick Ratio of 2.21. This indicates that AMPH is financially healthy and has no problem in meeting its short term obligations.
  • With a Quick ratio value of 2.21, AMPH perfoms like the industry average, outperforming 46.60% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.12
Quick Ratio 2.21
AMPH Yearly Current Assets VS Current LiabilitesAMPH Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • AMPH shows a slight negative growth in Earnings Per Share. In the last year, the EPS has decreased by -9.95%.
  • AMPH shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 61.62% yearly.
  • Looking at the last year, AMPH shows a decrease in Revenue. The Revenue has decreased by -0.03% in the last year.
  • Measured over the past years, AMPH shows a quite strong growth in Revenue. The Revenue has been growing by 17.82% on average per year.
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%

3.2 Future

  • Based on estimates for the next years, AMPH will show a small growth in Earnings Per Share. The EPS will grow by 0.14% on average per year.
  • The Revenue is expected to grow by 4.14% on average over the next years.
EPS Next Y-8.73%
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
EPS Next 5Y0.14%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%

3.3 Evolution

  • The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
AMPH Yearly Revenue VS EstimatesAMPH Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M
AMPH Yearly EPS VS EstimatesAMPH Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 1 2 3

More info and screens

Find the best growth stocksShow best growing peers

8

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 8.00, the valuation of AMPH can be described as very cheap.
  • Based on the Price/Earnings ratio, AMPH is valued cheaply inside the industry as 93.19% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 28.18. AMPH is valued rather cheaply when compared to this.
  • A Price/Forward Earnings ratio of 7.41 indicates a rather cheap valuation of AMPH.
  • Based on the Price/Forward Earnings ratio, AMPH is valued cheaper than 92.67% of the companies in the same industry.
  • AMPH is valuated cheaply when we compare the Price/Forward Earnings ratio to 28.01, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 8
Fwd PE 7.41
AMPH Price Earnings VS Forward Price EarningsAMPH Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 91.62% of the companies listed in the same industry.
  • Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMPH indicates a rather cheap valuation: AMPH is cheaper than 90.05% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 11.39
EV/EBITDA 7.83
AMPH Per share dataAMPH EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 5 10 15

4.3 Compensation for Growth

  • AMPH has an outstanding profitability rating, which may justify a higher PE ratio.
PEG (NY)N/A
PEG (5Y)0.13
EPS Next 2Y-1.9%
EPS Next 3Y0.87%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for AMPH!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (2/12/2026, 2:47:25 PM)

27.51

-1.08 (-3.78%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners74.02%
Inst Owner Change-0.72%
Ins Owners9.38%
Ins Owner Change-0.09%
Market Cap1.26B
Revenue(TTM)723.30M
Net Income(TTM)111.63M
Analysts78.33
Price Target32.2 (17.05%)
Short Float %10.93%
Short Ratio10.77
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.52%
Min EPS beat(2)10.58%
Max EPS beat(2)12.46%
EPS beat(4)3
Avg EPS beat(4)6.04%
Min EPS beat(4)-4.55%
Max EPS beat(4)12.46%
EPS beat(8)5
Avg EPS beat(8)4.79%
EPS beat(12)9
Avg EPS beat(12)18.2%
EPS beat(16)12
Avg EPS beat(16)16.54%
Revenue beat(2)1
Avg Revenue beat(2)0.23%
Min Revenue beat(2)-1.36%
Max Revenue beat(2)1.82%
Revenue beat(4)1
Avg Revenue beat(4)-1.21%
Min Revenue beat(4)-2.87%
Max Revenue beat(4)1.82%
Revenue beat(8)2
Avg Revenue beat(8)-0.96%
Revenue beat(12)6
Avg Revenue beat(12)0.35%
Revenue beat(16)9
Avg Revenue beat(16)0.62%
PT rev (1m)-0.45%
PT rev (3m)-4.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)5.73%
EPS NY rev (1m)0%
EPS NY rev (3m)3.62%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.16%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)0.62%
Valuation
Industry RankSector Rank
PE 8
Fwd PE 7.41
P/S 1.75
P/FCF 11.39
P/OCF 8.3
P/B 1.63
P/tB 6.18
EV/EBITDA 7.83
EPS(TTM)3.44
EY12.5%
EPS(NY)3.71
Fwd EY13.5%
FCF(TTM)2.42
FCFY8.78%
OCF(TTM)3.31
OCFY12.05%
SpS15.74
BVpS16.9
TBVpS4.45
PEG (NY)N/A
PEG (5Y)0.13
Graham Number36.17
Profitability
Industry RankSector Rank
ROA 6.7%
ROE 14.37%
ROCE 10.26%
ROIC 8.51%
ROICexc 10.49%
ROICexgc 20.29%
OM 20.73%
PM (TTM) 15.43%
GM 49.36%
FCFM 15.35%
ROA(3y)10.51%
ROA(5y)8.2%
ROE(3y)20.19%
ROE(5y)14.97%
ROIC(3y)12.92%
ROIC(5y)10.14%
ROICexc(3y)16.46%
ROICexc(5y)13%
ROICexgc(3y)29.66%
ROICexgc(5y)21.24%
ROCE(3y)15.59%
ROCE(5y)12.24%
ROICexgc growth 3Y24.9%
ROICexgc growth 5YN/A
ROICexc growth 3Y2.33%
ROICexc growth 5YN/A
OM growth 3Y20.68%
OM growth 5YN/A
PM growth 3Y15.39%
PM growth 5Y7.52%
GM growth 3Y3.84%
GM growth 5Y4.54%
F-Score5
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity 0.78
Debt/FCF 5.49
Debt/EBITDA 3
Cap/Depr 78.19%
Cap/Sales 5.71%
Interest Coverage 6.36
Cash Conversion 75.12%
Profit Quality 99.44%
Current Ratio 3.12
Quick Ratio 2.21
Altman-Z 2.47
F-Score5
WACC8.99%
ROIC/WACC0.95
Cap/Depr(3y)91.01%
Cap/Depr(5y)109.44%
Cap/Sales(3y)5.45%
Cap/Sales(5y)6.46%
Profit Quality(3y)95%
Profit Quality(5y)414.14%
High Growth Momentum
Growth
EPS 1Y (TTM)-9.95%
EPS 3Y41.58%
EPS 5Y61.62%
EPS Q2Q%-3.12%
EPS Next Y-8.73%
EPS Next 2Y-1.9%
EPS Next 3Y0.87%
EPS Next 5Y0.14%
Revenue 1Y (TTM)-0.03%
Revenue growth 3Y18.69%
Revenue growth 5Y17.82%
Sales Q2Q%0.33%
Revenue Next Year-0.8%
Revenue Next 2Y1.99%
Revenue Next 3Y2.7%
Revenue Next 5Y4.14%
EBIT growth 1Y-30.02%
EBIT growth 3Y43.24%
EBIT growth 5YN/A
EBIT Next Year1.1%
EBIT Next 3Y1.2%
EBIT Next 5Y5.95%
FCF growth 1Y-20.6%
FCF growth 3Y34.69%
FCF growth 5Y286.43%
OCF growth 1Y-12.89%
OCF growth 3Y29.62%
OCF growth 5Y38.57%

AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ

What is the fundamental rating for AMPH stock?

ChartMill assigns a fundamental rating of 6 / 10 to AMPH.


What is the valuation status of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?

ChartMill assigns a valuation rating of 8 / 10 to AMPHASTAR PHARMACEUTICALS IN (AMPH). This can be considered as Undervalued.


Can you provide the profitability details for AMPHASTAR PHARMACEUTICALS IN?

AMPHASTAR PHARMACEUTICALS IN (AMPH) has a profitability rating of 9 / 10.


What is the valuation of AMPHASTAR PHARMACEUTICALS IN based on its PE and PB ratios?

The Price/Earnings (PE) ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 8 and the Price/Book (PB) ratio is 1.63.